Can the Bounce Start Today on $NMRD?
img

Hello!

We continue to monitor our previous trade alert for a breakout above the 50 day moving average for further increased upside potential.

Today, we have a new NASDAQ trade alert that has in the past provided you with increased gain potential.

In addition, the company released breaking news this morning (details below).

New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)

We first brought NMRD to your attention earlier this year. Following our alert in September, NMRD rallied upwards of 56%.

This once again provides a potentially similar opportunity to the one in September.

NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor.”

NMRD could be one of the few undervalued companies in its sector.

Some of NMRD’s closest competitors in the glucose monitoring sector have been reaching new all-time highs in 2018.

What’s interesting is that NMRD could have a better product than its competitors…

The current leading products in the market are invasive, requiring a needle like sensor to be inserted under the skin.

NMRD’s “patent-protected technology” on the other hand is “non-invasive” using an “adhesive skin-patch connected to a rechargeable transmitter”.

This could potentially be a game changer, and not only for people with diabetes…

According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”

Moreover, since our last alert, NMRD has announced a number of potentially significant breaking developments that in our opinion Wall Street has overlooked.

Here is a summary from NMRD of it’s “Recent Highlights and Accomplishments”:

  • “SugarBEAT® reported positive interim data from clinic portion of study, planned for FDA submission.”
  • “Nemaura signed letter of intent for SugarBEAT® commercial launch in Qatar.”
  • “SugarBEAT® reported positive data for potential zero/reduced frequency of finger stick calibration.”
  • “Nemaura successfully developed predictive algorithms that will allow alarm functionality for sugarBEAT®.”

Dr. Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position to better support the expected commercial launch of sugarBEAT® in the United Kingdom in the coming weeks. Moreover, we anticipate achieving profitability in a significantly shorter term frame, as compared to other CGM providers, given the research and development costs we have incurred to date have been substantially lower, a trend we are confident will continue as we commercialize sugarBEAT®.”

Not only that, but NMRD recently announced:

“Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar”

“LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced that it has signed an exclusive license and distribution agreement with Al-Danah Medical Co. for the commercial launch of sugarBEAT® in Qatar in readiness for 2019 launch.

Qatar, has one of the world’s highest prevalence of diabetes, with 17% of the population diabetic and 23% pre-diabetic(1), and also has the world’s highest GDP per capita, and therefore represents a significant market for sugarBEAT®. Al-Danah Medical Company, part of the Almana Group, is a leading medical product distributor in Qatar, representing multiple global brands. 

Current global CGM usage rates are low and growing rapidly. The U.S. is the largest single market, where CGM is being used by an estimated 2.6% (630,000 users) of all diagnosed diabetics in 2018, representing annualised growth of 117%. SugarBEAT® is expected to receive CE Mark approval shortly and launch next month in the United Kingdom, an addresable market for CGM estimated at $1.38B per annum. The global addressable market for CGM is estimated at $82B per annum.(2)”

Plus:

“Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin”

“LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced that the Advanced Technologies and Treatments for Diabetes (ATTD) Conference has accepted its sugarBEAT® Clinical Performance Data Abstract for poster presentation at Berlin in February 2019.”

“ATTD is the leading international forum for clinicians to present and discuss the use of new technologies with the goal of improving the care of people with diabetes at the fastest possible pace, and has become synonymous with top calibre scientific programs.”

“Nemaura has also recently completed the clinical studies required for sugarBEAT® FDA De Novo 510(k) submission, and anticipates publishing this data on its website in the coming weeks, and submitting for FDA approval in March 2019.”

Moreover, just this morning NMRD announced potentially significant news that could be an additional catalyst for gain potential.

“Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering”

“LOUGHBOROUGH, England. Nemaura Medical Inc. (NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced the pricing of a “best efforts” public offering of  Company’s shares of common stock and warrants with expected total gross proceeds of up to $2.5 million. The offering is expected to close on or about December 20, 2018, subject to satisfaction of customary closing conditions.

“The offering was priced at $1.04 per share of common stock, with each share coupled with one five-year warrant to purchase one share of common stock, at an exercise price of $1.04 per share.”

“Nemaura plans to use the net proceeds from the offering for a U.S. FDA clinical trial, product launch in Europe and the development of a second generation of sugarBEAT®, as well as for general corporate and working capital purposes.”

Source: Yahoo Finance

NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.

If you agree, don’t miss this opportunity.

Source: PR1PR2PR3PR4PR5PR6PR7, PR8, WHOScientistWebsiteChart

 

Happy Trading!

Subscribe To Our Daily Newsletter

Free WordPress Themes, Free Android Games